



1ST JA-CHRODIS GOVERNING BOARD MEETING

18th February 2015

Venue: Spanish Research Council (CSIC), Rue du Trône, 62 (7th floor)
1050 Brussels, Belgium

Objectives:

- To present the Joint Action JA-CHRODIS.
- To present the expected role of the Governing Board (GB) in relation to the activities of JA-CHRODIS and future prospects.
- To share the expectations on JA-CHRODIS of the representatives of the GB (Member States, European Commission, WHO Regional Office for Europe).
- To approve the Terms of Reference for the functioning of the Governing Board.

Participants¹:

- Representatives of the Ministries of Health of the following EU Member States: AT, BE, BG, CY, HR, EE, FI, FR, DE, EL, LT, PT, SI, UK, ES and NO (16 nomination up to now).
- Representatives of the DG Santé and Chafea.
- Representatives of the WHO Regional Office for Europe.
- Representatives of the Executive Board (open session).

Discussion:

- The GB functions as a bridge between the activities of JA-CHRODIS and Member States' strategies on chronic diseases.
- One of GB's tasks consists on analyzing key deliverables of the JA-CHRODIS from the national policies on chronic diseases perspective.
- The input of the GB will contribute to improve the technical work and strategic progress of the JA-CHRODIS and generate synergies, collaboration and mutual learning amongst member States' health initiatives in chronic diseases. This will facilitate the future use of JA-CHRODIS gather experiences and developed tools in national policies/plans.
- Draft Terms of Reference of the Governing Board describing the work methodology for adoption.

The debates were addressed through guided questions previously sent and the answers or others suggestions received from the participants prior to the meeting.

Final agenda is attached as annex II.

¹ List of participant is attached as annex I.



Opening

Rubén Moreno, Secretary General for Health and Consumers of the Spanish Ministry of Health, Antonio L. Andreu, General Director of National Institute of Health Carlos III, and Michael Hübel, Head of Unit Health Programme and Diseases of the DG SANTÉ of the European Commission welcomed all the participants to the first meeting of the Governing Board and reflected on the importance and the burden of chronic diseases in Europe.

Following this, Carolina Rodríguez from the Spanish Ministry of Health introduced a summary of the schedule.

As in the first meeting of the GB, all the members introduced themselves in a *tour de table*.

Presentations

Juan E. Riese, Coordinator of the Joint Action CHRODIS, gave a brief explanation of the overall Joint Action CHRODIS, summarizing its main lines so all the members of the GB know what JA-CHRODIS is.

Paloma Casado, Deputy Director for Quality and Cohesion of the Spanish Ministry of Health, explained briefly what we have considered the role for the GB of the JA-CHRODIS might be. Joint Action CHRODIS aims to strongly contribute to reduce the burden of chronic diseases and to promote healthy ageing in Europe, even beyond the 3-years of the expected EU funding. To achieve this objective the participation of representatives of Ministries of Health of all the Member States is essential. The Governing Board members will advise the Joint Action strategic view, as well as facilitate the generation of synergies between JA-CHRODIS and national and international initiatives.

Afterwards, Juan Riese explained the main features of the terms of reference of this GB document which was sent to all the members before the meeting, so it could be approved.

Discussion

After the open session with the Executive Board (EB) of the Joint Action there was time for discussion with the valuable contribution of the EB. Members of the EB are the leaders and co-leaders of the work packages. Some of the questions from the members of the GB were:

- Regarding the potential establishment of a network and about the scheme work of the GB.



- Queries about what makes the Platform for Knowledge Exchange (PKE) different from others (we can already use) already developed. Enrique Bernal, Leader of WP4 explained that the helpdesk, the Clearinghouse and two expert reviews make the difference. After this explanation some of the members of the GB pointed out the suitability of making the PKE permanent and its usability by governments.

During the roundtable of the closed session of the GB there was time to debate on how the GB could work in order to achieve its objectives. Members of the GB could express their impressions about JA-CHRODIS following the guided questions for discussion and below are the main ideas, concerns and conclusions raised:

What is your general impression about the JA-CHRODIS and the activities of the work packages?

- o The interrelation of WP 5, 6 and 7 and their communication pathway. For some members of the GB WP 6 and 7 are working in an appropriate and specific way. However other members of the GB advised WP6 to be more accurate in their decisions because they are working on organizational aspects and have to be careful. Some other suggested that WP6 should be based on multi-risk rather than multimorbidity.
- o Regarding the WP good practices, some members of the GB would like to know how WP5 evaluates good practices. Others pointed out that the most important issue is how to exchange good practices.
- o Concerning the scope and purpose of JA-CHRODIS some members of the GB mentioned that it is related to cross border activities and therefore to the Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients' rights in cross-border healthcare and should take into account the decentralised structure of some member states.
- o Some members of the GB believed that JA-CHRODIS needs to have impact in the real world; it needs to look for evidence within the population not just within knowledge. Other suggestions were that JA-CHRODIS should consider which are the population's needs, what does the population want and how we can help professionals to face healthy ageing of the population. WP6 and 7 were considered the most important WPs and there were also views supporting the need of new health care models.
- o Some of the members of the GB are already collaborating with different WPs and they are in contact with them.
- o Policy questions about the organisation of JA-CHRODIS were also raised considering transferability to be the main point. However, some of the members of the GB believed that although JA-CHRODIS will face many challenges they expect good results and believed that an analysis tool is basic for sustainability.



How could the Governing Board work towards the sustainability of the actions of the JA-CHRODIS?

- The main ideas were that best practices, the involvement of all the members of the JA-CHRODIS and the PKE are the key points to reach the sustainability we are looking for.
- The GB is a good starting point to be able to link JA-CHRODIS to the real world.
- Implementation is needed to reach sustainability. We need to do it at the political, financial and technical levels.
- Working together can save resources and time but it is a significant challenge.

Finally, the Terms of Reference of the GB were approved and Paloma Casado made some closing remarks to finish the first meeting.

Closing remarks:

- The GB has added value for the JA-CHRODIS to facilitate the future use of JA-CHRODIS' gathered experiences and developed tools so it will contribute to the effectiveness and efficacy of national policies/plans.
- The GB should function as a bridge between the activities of JA-CHRODIS and Member States' strategies on chronic diseases, therefore a fluent communication on JA-CHRODIS progress is to be assured.
- The GB needs to work towards the sustainability of the JA-CHRODIS.



Annex I

PARTICIPANTS LIST

1. Institutional Representatives

SURNAME	NAME	ORGANIZATION	COUNTRY
ANDREU	Antonio	National Institute of Health Carlos III, ISCIII	Spain
BELTRAN	Alfonso	National Institute of Health Carlos III, ISCIII	Spain
CASADO	Paloma	Spanish Ministry of Health	Spain
HÜBEL	Michael	DG SANTE. European Commission	Belgium
MORENO	Rubén	Spanish Ministry of Health	Spain

2. JA-CHRODIS Governing Board Members

SURNAME	NAME	ORGANIZATION	COUNTRY
BOAVIDA	José	Ministry of Health	Portugal
BRUNOT	Alain	Ministère des affaires sociales, de la santé et des droits des femmes	France
BUDEWIG	Karen	Federal Ministry of Health	Germany
COLLEN-GODMAN	Sarah	Department of Health	United Kingdom
FOTEVA	Elvira	Directorate "Health Policy" of the Ministry of Health	Bulgaria
GUERRA	Raineri	Ministry of Health	Italy
HUBER	Manfred	WHO Regional Office for Europe	Denmark



SURNAME	NAME	ORGANIZATION	COUNTRY
KALIVA	Fofa	Ministry of Health	Greece
PETRIČ	Kerstin	Ministry of Health	Slovenia
KÖHLER	Kristina	Ministry of Social Affairs	Estonia
MCSHANE	Martin	Department of Health	United Kingdom
RODRIGUEZ	Carolina	Spanish Minsitry of Health	Spain
SARLIO-LÄHTEENKORVA	Sirpa	Ministry of Social Affairs and Health	Finland
SKASET	Maren	Ministry of Health	Norway

3. JA-CHRODIS Executive Board Members

SURNAME	NAME	ORGANIZATION	COUNTRY
AREVALO	Gonzalo	National Institute of Health Carlos III, ISCIII	Spain
BELIZAIRE	Marie Roseline Darnycka	National Institute of Health Carlos III, ISCIII	Spain
BERNAL	Enrique	Instituto Aragonés de Ciencias de la Salud, IACS	Spain
CARRION	Carme	Agència de Qualitat i Avaluació Sanitàries de Catalunya, AQuAS	Spain
CHAVARRIA	Teresa	National Institute of Health Carlos III, ISCIII	Spain
DEL RÍO	Catalina	National Institute of Health Carlos III, ISCIII	Spain
ESPALLARGUES	Mireia	Agència de Qualitat i Avaluació Sanitàries de Catalunya, AQuAS	Spain



SURNAME	NAME	ORGANIZATION	COUNTRY
GALLINAT	Anna	EUROHEALTHNET	Belgium
JUREVIČIENĖ	Elena	Vilniaus Universiteto Ligonės Santariškių Klinicos, VULSK	Lithuania
KUNKEL	Thomas	Federal Centre for Health Education, BZgA	Germany
LAUNA	Ramón	Instituto Aragonés de Ciencias de la Salud, IACS	Spain
LOMBARDO	Flavia	Istituto Superiore di Sanità, ISS	Italy
MAGGINI	Marina	Istituto Superiore di Sanità, ISS	Italy
MAMMARELLA	Federica	Agenzia Italiana del Farmaco, AIFA	Italy
MANNING	Eibhilin	DG SANTE. European Commission	Belgium
NAVICKAS	Rokas	Vilniaus Universiteto Ligonės Santariškių Klinicos, VULSK	Lithuania
ONDER	Graziano	Agenzia Italiana del Farmaco, AIFA	Italy
PHILIPP	Wolfgang	DG SANTE, European Commission	Luxemburg
RIBEIRO	Rogério	Associação Protectora dos Diabéticos de Portugal, APDP	Portugal
RIESE	Juan E.	National Institute of Health Carlos III, ISCIII	Spain
ROBLES	Noemí	Agència de Qualitat i Avaluació Sanitàries de Catalunya, AQuAS	Spain
STEGEMAN	Ingrid	EUROHEALTHNET	Belgium
YAZBECK	Anne-Marie	Chafea, European Commission	Luxemburg
ZALETEL	Jelka	National Institute of Public Health, NIJZ	Slovenia



Annex II

AGENDA

Open session with the Executive Board	
14:30 – 14:45	<p>Opening</p> <p>Rubén Moreno, Secretary General for Health and Consumers. Spanish Ministry of Health</p> <p>Antonio L. Andreu, General Director of National Institute of Health Carlos III</p> <p>Michael Hübel, Head of Unit Health Programme and Diseases. DG SANTE. European Commission</p>
14:45 - 14:50	<p>Introduction to the meeting, facilitator: Carolina Rodríguez, Spanish Ministry of Health.</p>
14:50-15:10	<p>Tour de table</p>
15:10-15:20	<p>Brief presentation of the overall Joint Action JA-CHRODIS.</p> <p>Juan E. Riese, Coordinator JA-JA-CHRODIS</p>
15:20-15:25	<p>Role of the Governing Board (GB). Paloma Casado, Deputy Director for Quality and Cohesion. Spanish Ministry of Health</p>
15:25-15:30	<p>Presentation of the Terms of Reference for the functioning of GB. Juan E. Riese, Coordinator JA-JA-CHRODIS</p>
15:30- 16:10	<p>Discussion</p>
16:10 - 16:30	<p>Coffee break</p>
Closed session of the Governing Board	
16:30 - 17:30	<p>Roundtable: guided questions for discussion</p> <p>Facilitator: Carolina Rodríguez. Spanish Ministry of Health</p>
17:30- 17:40	<p>Formal approval of the Terms of Reference of the GB</p>
17:40 - 17:50	<p>Closing remarks</p> <p>Paloma Casado, Deputy Director for Quality and Cohesion. Spanish Ministry of Health</p>